

**Bone Biologics Corporation**  
**2 Burlington Woods Drive, Suite 100**  
**Burlington, MA 01803**

January 22, 2024

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
Attn: Jane Park

Re: **Bone Biologics Corporation**  
**Registration Statement on Form S-3**  
**File No. 333-276412**

Ladies and Gentlemen:

In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, Bone Biologics Corporation, a Delaware corporation (the “Registrant”), hereby requests that the effectiveness of the registration statement on Form S-3 (File No. **333-276412**), initially filed with the U.S. Securities and Exchange Commission on January 5, 2024, as amended by the Pre-Effective Amendment No. 1 filed on January 17, 2024, be accelerated so that the registration statement becomes effective at 4:00 p.m. Eastern Time on January 24, 2024 or as soon thereafter as practicable.

If you have any questions or comments, please contact Alexander R. McClean of Harter Secrest & Emery at (585) 231-1248.

Very truly yours,

Bone Biologics Corporation

By: /s/ Jeffrey Frelick

Jeffrey Frelick  
President and Chief Executive Officer

---